OR WAIT null SECS
Partnership enables Moderna to leverage Caris' library of de-identified, multi-modal data and analytics.
Caris has announced a new agreement with Moderna in support of Moderna's oncology and novel therapeutics initiatives.
Through this multi-year agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including facilitation of clinical trial design.
"Partnering with Caris Life Sciences will support Moderna's oncology portfolio with clinico-genomics data from Caris' industry-leading and comprehensive suite of integrated precision medicine capabilities," stated Praveen Aanur, MD, MPH, MBA, vice president, oncology therapeutic area head of Moderna in a press release.
"We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives," said David Spetzler, MS, PhD, MBA, president of Caris Life Sciences. "The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna's innovative medicines."
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics. (24 October 2023). Cision PR Newswire.